DMAC_OUT_1 [2025-04-28 13:54:03 -0400] 5930 Bytes | 1630 tokens | Cum: 1630 tkns (20.38% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 1:54 PM on Mon Apr 28, 2025, and I'm firing up the spotlight on DiaMedica Therapeutics (DMAC), moving from $4.04 to $4.75. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: DiaMedica Therapeutics (DMAC)
IPO: 2007-11-29 (17 Years Ago)
Market Cap: $151,280,480
Shares Outstanding: 42,860,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Here’s a list of headlines for DiaMedica Therapeutics:

Apr-15-25 08:54PM - DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve
Mar-19-25 03:00AM - DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ...
Mar-18-25 10:22PM - Q4 2024 DiaMedica Therapeutics Inc Earnings Call
Mar-17-25 04:30PM - DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
Mar-11-25 08:23AM - DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
Feb-24-25 08:30AM - DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors
Feb-20-25 08:15AM - DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
Feb-10-25 04:15PM - DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Dec-03-24 08:25AM - DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
Nov-15-24 02:06AM - Q3 2024 DiaMedica Therapeutics Inc Earnings Call
Nov-13-24 04:20PM - DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Nov-13-24 04:20PM 04:05PM - DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Nov-12-24 08:23AM - DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
Nov-06-24 08:32AM - DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
Oct-10-24 05:28AM - DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial
Oct-09-24 08:27AM - DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Sep-04-24 04:15PM - DiaMedica Therapeutics Upcoming Conference Participation
Aug-07-24 04:15PM - DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
Aug-01-24 09:40AM - Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
Aug-01-24 09:40AM 08:20AM - DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Jul-11-24 08:00AM - DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Jul-01-24 08:00AM - DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-04-18T14:06:00Z - DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
B2 - 2024-04-15T13:35:05Z - DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
B3 - 2023-09-19T13:40:09Z - Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
B4 - 2023-08-31T13:40:11Z - Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
B5 - 2023-06-22T15:02:26Z - Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
B6 - 2022-12-02T13:43:37Z - $1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for DiaMedica Therapeutics (DMAC).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

DMAC_OUT_3 [2025-04-28 13:54:03 -0400] 664 Bytes | 188 tokens | Cum: 1820 tkns (22.75% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2257798/diamedica-dmac-up-as-stroke-study-dosing-begins-post-relaunchDiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_5 [2025-04-28 13:54:04 -0400] 887 Bytes | 272 tokens | Cum: 2094 tkns (26.17% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-23T08:34:33Z - $DMAC | ($DMAC) Long Term Investment Analysis (DMAC)...
A2 - 2025-04-20T15:33:22Z - DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update...
A3 - 2025-04-16T00:56:14Z - DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve (NASDAQ:DMAC)...
A4 - 2025-04-15T09:19:09Z - Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Applied D...
A5 - 2025-04-07T01:16:22Z - $DMAC | Learn to Evaluate ($DMAC) using the Charts (DMAC)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

DMAC_OUT_7 [2025-04-28 13:54:05 -0400] 1181 Bytes | 315 tokens | Cum: 2411 tkns (30.14% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**$DMAC | ($DMAC) Long Term Investment Analysis (DMAC)**Date: 2025-04-23Source: {'uri': 'news.stocktradersdaily.com', 'dataType': 'news', 'title': 'Stock Traders Daily'}URL: https://news.stocktradersdaily.com/news_release/38/(DMAC)+Long+Term+Investment+Analysis_042325040002.htmlOur Signals help define rules-based Trading Plans predicated on the Basic Rules of Tehnical Analysis. Take a trial, review our Index ETF Signals, macro, more...

April 23, 2025, 04:00 am ET, BY Randall S.- Contributor| Editor: Thomas H. Kee Jr. (Follow on LinkedIn)

Technically, Diamedica Therapeutics Inc. (NASDAQ: DMAC) provides opportunities for traders who are watching the price of the stock oscillate over time.

Warning:

This is a static report, the data below was valid at the time of the publication, but support and resistance levels for DMAC change over time, so the report should be updated regularly. R

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_9 [2025-04-28 13:54:06 -0400] 1181 Bytes | 261 tokens | Cum: 2674 tkns (33.42% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): eal Time updates are provided to subscribers. Unlimited Real Time Reports.

Subscribers also receive market analysis, stock correlation tools, macroeconomic observations, timing tools, and protection from market crashes using Evitar Corte.

Instructions:

The rules that govern the data in this report are the rules of Technical Analysis. For example, if DMAC is testing support buy signals surface, and resistance is the target. Conversely, if resistance is being tested, that is a sign to control risk or short, and support would be the downside target accordingly. In each case, the trigger point is designed to be both an ideal place to enter a position (avoid trading in the middle of a trading channel), and it acts as a level of risk control too.

Swing Trades, Day Trades, and Longer term Trading Plans:

This data is refined to differentiate trading plans for Day Trading, Swing Trading, and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_11 [2025-04-28 13:54:07 -0400] 417 Bytes | 112 tokens | Cum: 2788 tkns (34.85% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): Long Term Investing plans for DMAC too. All of these are offered below the Summary Table.

Support and Resistance Plot Chart for DMAC

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_13 [2025-04-28 13:54:09 -0400] 1079 Bytes | 283 tokens | Cum: 3073 tkns (38.41% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-03-17 10-K Item 7.

Management s Discussion and Analysis of Fin Cond and Results of Oper

##TABLE_END

The following Mgts Discussion and Analysis of Fin Cond and Results of Oper is based upon accounting principles generally accepted in the United...

S3 - 2025-03-17 8-K Item 2.02. Results of Oper and Fin Cond.

On March 17, 2025, DiaMedica Therapeutics Inc. (the Company) announced its CONS financial results for the year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Curr Repo...

S4 - 2025-02-24 8-K Item 7.01 Regulation FD Disclosure.

The Company announced the appointment of Daniel J. OConnor as a director in a press release issued on February 24, 2025, which is attached as Exhibit 99.1 to this Curr Report on Form 8-K and incorporated herein by reference.

The informati...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DMAC_OUT_15 [2025-04-28 13:54:10 -0400] 1181 Bytes | 238 tokens | Cum: 3313 tkns (41.41% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7.

Management s Discussion and Analysis of Financial Condition and Results of Operations

##TABLE_END

The following Managements Discussion and Analysis of Financial Condition and Results of Operations is based upon accounting principles generally accepted in the United States of America and discusses the financial condition and results of operations for DiaMedica Therapeutics Inc. and our subsidiaries for the years ended December 31, 2024 and 2023.

This discussion should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. The following discussion contains forward-looking statements that involve numerous risks and uncertainties. Our actual results could differ materially from the forward-looking statements as a result of these risks and uncertainties. See Cautionary Note Regarding Forward-Looking Statements

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_17 [2025-04-28 13:54:11 -0400] 1181 Bytes | 281 tokens | Cum: 3596 tkns (44.95% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): for additional cautionary information.

Business Overview

We are a clinical stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Our lead candidate DM199 (rinvecalinase alfa; rhKLK1) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein (serine protease enzyme) to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of AIS and porcine KLK1, for the treatment of cardio renal disease, including hypertension. Our current focus is on the treatment of AIS and PE. We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_19 [2025-04-28 13:54:12 -0400] 1181 Bytes | 282 tokens | Cum: 3880 tkns (48.50% of 8k)
==========================================================================

Showing S2 (chunk 3 of 6): a therapy for AIS and PE. Longer term, we plan to develop DM300, our patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, as a potential therapy for severe acute pancreatitis.

Our lead candidate DM199 is a recombinant form of human tissue kallikrein-1 (rhKLK1) which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and the first and only rhKLK1 undergoing global clinical development studies in both AIS and PE. DM199 has been granted Fast Track designation from the FDA for the treatment of AIS. Naturally occurring KLK1 (extracted from human urine or porcine pancreas) has been an approved therapeutic agent in Asia for decades in the treatment of AIS and hypertension associated with cardiorenal disease. DM199 is produced using recombinant DNA technology without the need for extracted human or animal tissue sources and thereby eli

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_21 [2025-04-28 13:54:16 -0400] 1181 Bytes | 261 tokens | Cum: 4143 tkns (51.79% of 8k)
==========================================================================

Showing S2 (chunk 4 of 6): minates risk of pathogen transmission. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that may enhance microcirculatory blood flow and tissue perfusion by increasing production of NO, PGI2 and EDHF. In the case of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis. In preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta, potentially disease modifying outcomes improving both maternal and perinatal outcomes.

Our product development pipeline is as follows:

We are d

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_23 [2025-04-28 13:54:16 -0400] 1181 Bytes | 267 tokens | Cum: 4412 tkns (55.15% of 8k)
==========================================================================

Showing S2 (chunk 5 of 6): eveloping DM199 to address two major critical unmet needs. In AIS, up to 80% of AIS patients are not eligible for treatment with currently approved clot-busting (thrombolytic) drugs or catheter-based clot removal (mechanical thrombectomy). DM199 is intended to enhance collateral blood flow and boost neuronal survival in the ischemic penumbra and inhibit neuronal cell death (apoptosis) while promoting neuronal remodeling and neoangiogenesis and offer a treatment option for patients who have otherwise no therapeutic options. In PE, there are currently no approved agents in any global market to safely lower maternal blood pressure and/or reduce the risk of fetal growth restriction. Historically, the major issue is that traditional vasodilators that are commonly used to reduce essential hypertension (eg, beta-blockers, angiotensin converting enzyme inhibitors (ACEi)) can readily cross the pl

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_25 [2025-04-28 13:54:18 -0400] 790 Bytes | 181 tokens | Cum: 4595 tkns (57.44% of 8k)
==========================================================================

Showing S2 (chunk 6 of 6): acenta and enter into the fetal circulation and cause harm to the developing fetus. We believe that DM199 is uniquely suited to treat PE since its inherent molecular size (~26 kilodaltons (KD)) is typically too large to cross the blood-placental barrier but may simultaneously reduce blood pressure and enhance microcirculatory perfusion to the maternal organs and placenta. DM199 has the potential to not only address hypertension of PE but also confer disease modifying outcomes for both maternal and p...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DMAC_OUT_27 [2025-04-28 13:54:24 -0400] 6706 Bytes | 1812 tokens | Cum: 6409 tkns (80.11% of 8k)
==========================================================================

This is our set of metrics for DiaMedica Therapeutics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+----------------------+
| Volume: 60,117 | Perf Month: 7.97% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 85.89K | Perf Quarter: -26.24% | Short Float: 1.54% | ROE: -53.27% |
+--------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1.07 | Index: - | Short Ratio: 4.32 | ROI: -59.69% |
+--------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 57.80 | Market Cap: 191.57M | Short Interest: 0.37M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.35 | Shs Outstand: 42.82M | Beta: 1.29 | EPS Surprise: -4.35% |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA20: 20.27% | Shs Float: 24.06M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA50: -8.57% | Inst Own: 16.04% | Sales past 5Y: 0.00% | Earnings: Mar 17 AMC |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA200: -3.97% | Insider Own: 43.87% | Employees: 28 | |
+--------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 26.63% | Insider Trans: 0.00% | Debt/Eq: 0.01 | |
+--------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by DiaMedica Therapeutics officers or majority shareholders (if available).

Inside Trans: DiaMedica Therapeutics Inc. (DMAC) by Pilnik Richard D. (Unknown Title) on 2025-04-07
- Voting Common Shares, no par value per share: 24000 shares at $2.11 (D)
- Stock Option (right to buy): 24000 shares at $0 (D)

No transactions recorded.

Inside Trans: DiaMedica Therapeutics Inc. (DMAC) by O'Connor Daniel J. (Unknown Title) on 2025-02-20
- Stock Option (right to buy): 64242 shares at $0 (D)

Inside Trans: DiaMedica Therapeutics Inc. (DMAC) by Giuffre Randall Michael (Unknown Title) on 2025-02-13
- Voting Common Shares, no par value per share: 12000 shares at $2.11 (D)
- Voting Common Shares, no par value per share: 5000 shares at $3.65 (D)
- Stock Option (right to buy): 12000 shares at $0 (D)
- Stock Option (right to buy): 5000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -24444000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.75
Average Volume: 86935.7
30-Day High: 4.75
30-Day Low: 3.38

[Detailed Financials: TTM 2024]
- Total Assets: $46,345,000.00
- Total Liabilities: $5,627,000.00
- Total Equity: $40,718,000.00
- Current Assets: $44,610,000.00
- Current Liabilities: $5,390,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-24,444,000.00
- Gross Profit: N/A
- Operating Income: $-26,681,000.00
- Earnings Per Share (EPS): -0.6

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-1,518,000.00

[Detailed Financials: FY 2024]
- Total Assets: $46,345,000.00
- Total Liabilities: $5,627,000.00
- Total Equity: $40,718,000.00
- Current Assets: $44,610,000.00
- Current Liabilities: $5,390,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-24,444,000.00
- Gross Profit: N/A
- Operating Income: $-26,681,000.00
- Earnings Per Share (EPS): -0.6

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-1,518,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of DiaMedica Therapeutics (DMAC).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about DiaMedica Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because DMAC is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for DMAC.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, DMAC could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect DMAC to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of DiaMedica Therapeutics.

11) ETHICAL_RATING[]
Rate DiaMedica Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of DiaMedica Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

DMAC_IN_29 [2025-04-28 13:54:24 -0400] 126 Bytes | 29 tokens | Cum: 6644 tkns (83.05% of 8k)
==========================================================================

====================================
[2025-04-28 13:54:24] # Analysis Completed
Elapsed Time: 22.62 seconds